These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 9234925

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC).
    Joly F, Héron JF, Kerbrat P, Chauvergne J, Rios M, Mayer F, Chinet-Charrot P, Goupil A, Lebrun-Jezekova D, Vennin D, Lhommé C, Macé-Lesec'h J, Crouet H.
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):361-8. PubMed ID: 10985895
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Phase II study of carboplatin and cyclophosphamide combination chemotherapy for the treatment of advanced ovarian cancer.
    Teeling M, Carney DN.
    Eur J Gynaecol Oncol; 1990 Sep; 11(3):219-24. PubMed ID: 2209642
    [Abstract] [Full Text] [Related]

  • 30. Carboplatin versus cisplatin in ovarian cancer.
    Alberts DS.
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):88-90. PubMed ID: 7481869
    [Abstract] [Full Text] [Related]

  • 31. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
    van der Burg ME, Onstenk W, Boere IA, Look M, Ottevanger PB, de Gooyer D, Kerkhofs LG, Valster FA, Ruit JB, van Reisen AG, Goey SH, van der Torren AM, ten Bokkel Huinink D, Kok TC, Verweij J, van Doorn HC.
    Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
    [Abstract] [Full Text] [Related]

  • 32. Prospective sequential trials of induction weekly cisplatin followed by monthly cisplatin, doxorubicin, cyclophosphamide and paclitaxel and cisplatin in optimal (< or = 1 cm) stage III and IV ovarian cancer.
    Piver MS, Eltabbakh GH, Hempling RE, Recio FO, Blumenson LE.
    Eur J Gynaecol Oncol; 1998 Oct; 19(1):5-10. PubMed ID: 9476049
    [Abstract] [Full Text] [Related]

  • 33. Cyclophosphamide, epirubicin and cisplatin (CEP) versus epirubicin plus cisplatin (EP) in stage Ic-IV ovarian cancer: a randomized phase III trial of the Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg.
    Wils J, van Geuns H, Stoot J, Bergmans M, Boschma F, Bron H, Degen J, Erdkamp F, van Erp J, Haest J, Iding R, Lalisang F, de Pree N, de Rooy C, Snijders M, Schepers J, Vreeswijk J, Wals J, Werter M, Wetzels L, Smeets J, Schouten L.
    Anticancer Drugs; 1999 Mar; 10(3):257-61. PubMed ID: 10327029
    [Abstract] [Full Text] [Related]

  • 34. Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic co-operative oncology group study.
    Skarlos DV, Aravantinos G, Kosmidis P, Pavlidis N, Gennatas K, Beer M, Mylonakis N, Makrantonakis P, Klouvas G, Karpathios S, Linardou H, Konstantaras C, Fountzilas G.
    Eur J Cancer; 1996 Mar; 32A(3):421-8. PubMed ID: 8814685
    [Abstract] [Full Text] [Related]

  • 35. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.
    Bolis G, Scarfone G, Giardina G, Villa A, Mangili G, Melpignano M, Presti M, Tateo S, Franchi M, Parazzini F, Associazione per la Ricerca in Ginecologia Oncologia (ARGO 96) Study Group.
    Gynecol Oncol; 2001 Apr; 81(1):3-9. PubMed ID: 11277642
    [Abstract] [Full Text] [Related]

  • 36. Carboplatin/cyclophosphamide combination chemotherapy for advanced ovarian cancer.
    Teeling M, Hayes Y, Fitzmaurice B, McGing P, Carney DN.
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):102-6. PubMed ID: 1411620
    [Abstract] [Full Text] [Related]

  • 37. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
    Hainsworth JD, Grosh WW, Burnett LS, Jones HW, Wolff SN, Greco FA.
    Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
    [Abstract] [Full Text] [Related]

  • 38. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A, Lück HJ, Meier W, Möbus V, Costa S, Richter B, Warm M, Bauknecht T, Schröder W, Olbricht S, Nitz U, Jackisch C.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [Abstract] [Full Text] [Related]

  • 39. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
    Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F, Multicentre Italian Trials in Ovarian cancer (MITO-7), Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO), Mario Negri Gynecologic Oncology (MaNGO), European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10), Gynecologic Cancer InterGroup (GCIG) Investigators.
    Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
    [Abstract] [Full Text] [Related]

  • 40. Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer.
    Gershenson DM, Morris M, Burke TW, Levenback C, Kavanagh JJ, Fromm GL, Silva EG, Warner D, Wharton JT.
    Gynecol Oncol; 1995 Sep; 58(3):349-55. PubMed ID: 7672700
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.